Medmix AGMDMXF 61 ROC (Joel Greenblatt) % is 4.27% as of Dec. 2025, which is 48% below its 10-year median of 8.16. GuruFocus rates MDMXF with a GF Score™ of 61/100 and a GF Value™ of $26.13. The stock has 7 warning signs investors should review. Among 3,064 Industrial Products companies, Medmix AG ranks worse than 61.26% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Medmix AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 4.27%.
The historical rank and industry rank for Medmix AG's ROC (Joel Greenblatt) % or its related term are showing as below:
MDMXF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 1.91 Med: 8.16 Max: 39.92
Current: 7.12
During the past 8 years, Medmix AG's highest ROC (Joel Greenblatt) % was 39.92%. The lowest was 1.91%. And the median was 8.16%.
MDMXF's ROC (Joel Greenblatt) % is ranked worse than 61.26% of 3064
companies
in the Industrial Products industry
Industry Median: 11.69
vs MDMXF: 7.12
Medmix AG's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -23.90% per year.
Medmix AG (OTCPK:MDMXF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
The historical data trend for Medmix AG's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDMXF vs GEV, ETN, PH: ROC (Joel Greenblatt) % Comparison
For the Specialty Industrial Machinery subindustry, Medmix AG's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medmix AG ROC (Joel Greenblatt) % vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Medmix AG's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Medmix AG's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 4.27% mean?
Medmix AG (MDMXF) has a ROC (Joel Greenblatt) % of 4.27% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Medmix AG and its competitors. This is 48% below median its historical median of 8.16. Over the past decade, Medmix AG's ROC (Joel Greenblatt) % has ranged from 1.91 to 39.92. According to the industry distribution chart, Medmix AG ranks #1877 out of 3064 companies in the Industrial Products industry, placing it in the top 61.3%.
Is Medmix AG's ROC (Joel Greenblatt) % too high?
Medmix AG's current ROC (Joel Greenblatt) % of 4.27% is 48% below median its 10-year median of 8.16. Over the past 10 years, this metric has ranged from a low of 1.91 to a high of 39.92. The Industrial Products industry median ROC (Joel Greenblatt) % is 11.69. Medmix AG's value of 4.27% is 63.5% below this industry median. Based on the distribution chart, Medmix AG ranks #1877 out of 3064 companies in the Industrial Products industry, which is below the industry midpoint. Overall, Medmix AG has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Medmix AG's ROC (Joel Greenblatt) % compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Medmix AG ranks #1877 out of 3064 companies for ROC (Joel Greenblatt) %. This places Medmix AG in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 11.69. Medmix AG's value of 4.27% is 63.5% below this benchmark. Historically, Medmix AG's own ROC (Joel Greenblatt) % has ranged from 1.91 to 39.92 over the past decade. While the company's 10-year median is 8.16 vs. the industry median of 11.69, Medmix AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for an Industrial Products company?
The median ROC (Joel Greenblatt) % among Industrial Products companies is 11.69, based on 3,064 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medmix AG's current ROC (Joel Greenblatt) % of 4.27% is 63.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Medmix AG and its competitors. For the Industrial Products industry, the median ROC (Joel Greenblatt) % is 11.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medmix AG's current ROC (Joel Greenblatt) % is 4.27%, which is 48% below median its own 10-year median of 8.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medmix AG stock overvalued right now?
Medmix AG (MDMXF) has a current ROC (Joel Greenblatt) % of 4.27%. The stock's GF Value™ is $26.13, compared to a current price of $17.40 — trading 33.4% below its estimated fair value. The current ROC (Joel Greenblatt) % is 4.27%, which is 48% below median its 10-year median of 8.16 and 63.5% below the Industrial Products industry median of 11.69. Medmix AG's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Medmix AG (MDMXF), the current ROC (Joel Greenblatt) % is 4.27% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medmix AG (MDMXF) Overvalued in 2026?
Based on GuruFocus' analysis, Medmix AG stock appears to be undervalued.
The current stock price of $17.40 is trading 33.4% below its estimated GF Value™ of $26.13.
Key valuation signals for MDMXF:
ROC (Joel Greenblatt) %: 4.27% (48% below median its 10-year median of 8.16)
GF Value™: $26.13 vs. price of $17.40 (33.4% below fair value)
Industry Position: 63.5% below the Industrial Products median (#1877 of 3064)
No single metric tells the full story. See the MDMXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medmix AG designs and produces high-precision delivery devices for the healthcare, consumer and industrial segments. Its segments are Healthcare, Consumer & Industrial, and Others. The Healthcare segment focuses on delivery devices for the drug delivery, surgery, and dental markets, including injection pens for subcutaneous drug delivery, surgical delivery devices, and mixing and delivery systems for the dental consumable industry. The Consumer & Industrial segment focuses on delivery devices used for industrial applications such as adhesives in construction, electronics, automotive, and aerospace, as well as consumer markets such as beauty and microbrush applications. The company operates in Europe, the Middle East and Africa, the Americas, and Asia-Pacific.
61GF Score
Get the complete analysis for MDMXF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDMXF has been successfully added to your 
